---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-029405"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2023-03-07T23:59:59+00:00"
generated_at: "2026-06-18T10:35:02.620038+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nuvectis Pharma FY2022 net loss $19.1M; cash $20M; NXP800 Fast Track; NXP900 IND expected 1H23

## Summary
- Cash and short-term investments $20.0M at Dec 31, 2022, up from $5.7M.
- Net loss $19.1M vs $12.9M in 2021; R&D expense $13.2M; G&A $6.0M.
- NXP800 granted Fast Track Designation for platinum-resistant, ARID1A-mutated ovarian cancer.
- ENGOT and GOG Foundation to lead NXP800 Phase 1b trial in ovarian cancer.
- NXP900 IND submission and Phase 1 start expected first half 2023.

## SEC filing metadata
- accession: 0001104659-23-029405
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2023-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465923029405/0001104659-23-029405-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465923029405/tm238641d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-029405
- JSON: https://secwatch.observer/filing/0001104659-23-029405.json
- Plain text: https://secwatch.observer/filing/0001104659-23-029405.txt

## Key facts
- Earnings Releases
  Nuvectis Pharma, Inc. reported the fiscal year ended December 31, 2022 results: net income $19.1 million.
  - Period: the fiscal year ended December 31, 2022
  - Net income: $19.1 million
  - Result: reported results
  source text: Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the fiscal year ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1875558/000110465923029405/0001104659-23-029405-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.